October 30, 2012Open Access

Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Bendamustine showed an encouraging high response rate across the two major PTCL subtypes, independent of age and prior treatment, with acceptable toxicity in refractory or relapsed T-cell lymphoma.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Damaj et al. (Tue,) studied this question.

synapsesocial.com/papers/69d97e215e5bcb4e3b836d62 https://doi.org/https://doi.org/10.1200/jco.2012.43.7285

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes2008 · 2,101 citations
2Clinical Trials : A Methodologic Perspective1997 · 804 citations
3Clinical Trials2005 · 358 citations
4Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas1999 · 3,490 citations
5Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors2011 · 6 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo